Elevated IL-6 levels in morphea patients have prompted trials of tocilizumab, an anti-IL-6 monoclonal antibody, with intravenous administration leading to improvement in severe pediatric cases, especially in combination with methotrexate [29]. Here, IL6 is linked to localized scleroderma.